<DOC>
	<DOCNO>NCT01095081</DOCNO>
	<brief_summary>Prospective , non-interventional , multi-center study . The observation period subject cover treatment period GadovistÂ® . For patient , treat physician nurse document demographic , medical data , safety parameter treatment sign symptom visit . Patients severe renal impairment followed-up 3 month phone call investigator line routine practice . Data audit/monitoring source data verification do subset sit patient</brief_summary>
	<brief_title>GARDIAN , Gadovist Routine Diagnostic Magnetic Resonance Imaging Administration Non-selected Patients</brief_title>
	<detailed_description>Evaluate safety tolerability Gadovist patient require contrast-enhanced MRI .</detailed_description>
	<criteria>Patients undergo contrast enhance Magnetic Resonance Imaging Gadobutrol ( Gadovist ) . There exclusion criterion beyond contraindication contain Summary Product Characteristics ( hypersensitivity active substance excipients ) warning .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>